ReVance Therapeutics Inc.
This article was originally published in Start Up
After spending its first three years quietly amassing preclinical and clinical data on its pipeline for aesthetic and therapeutic dermatology, Essentia Biosystems is ready to make some noise. It has unveiled a new name, ReVance Therapeutics Inc., will soon announce some key hires, and is preparing to enter the clinic with its lead candidate, a topical, "wipe-on" form of botulinum toxin delivered with the company's proprietary technology for transporting large molecule drugs through the skin.
You may also be interested in...
New energy-based fat removal technology is emerging as the next frontier in noninvasive energy-based aesthetics, but questions remain as to its mechanism of action in treating fat or cellulite. There is no question that patient demand is strong, and there are a number of products and techniques under development.
Judging from the number of recent well-financed company launches and the size of follow-on rounds for established players, specialty dermatology hasn't lost its allure for investors. Add to that two successful 2004 IPOs--for Barrier Therapeutics Inc. and Cutera Inc.--and it's clear that aesthetic and therapeutic dermatology are still good bases for building specialty pharmaceutical businesses.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)